1 / 3

Mabtas RA500mg injection - Rituximab | Apple Pharmaceuticals

Mabtas RA 500mg is indicated for the treatment for patients suffering with chronic Lymphocytic Leukemia, Rituximab belongs type of monoclonal antibody which aims the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes

sharonpaula08
Download Presentation

Mabtas RA500mg injection - Rituximab | Apple Pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Mabtas RA 500mg Mabtas RA 500mg is indicated for the treatment for patients suffering with certain types of Non- Hodgkin’s Lymphoma. Mabtas RA 500mg is indicated for the treatment for patients suffering with chronic Lymphocytic Leukemia Brand name :Mabtas RA Active component : Rituximab Strength :500mg Manufactured by :Biochem Pharma Dosage form :injection Pack of 50ml in 1 vial Pharmacology Rituximab belongs type of monoclonal antibody which aims the CD20 antigen expressed on the surface of pre-B and mature B-lymphocytes. Upon binding to CD20, rituximab intercedes B-cell lysis. Potential mechanisms of cell lysis contain complement dependent cytotoxicity (CDC) and antibody dependent cell intercede cytotoxicity (ADCC). B cells are believed to play a role in the

  2. pathogenesis of rheumatoid arthritis (RA) and along with chronic synovitis. In this setting, B cells may be work at multiple sites in the autoimmune/inflammatory process, involving through production of rheumatoid factor (RF) and other autoantibodies, antigen presentation, T-cell activation, and/or proinflammatory cytokine production. Precautions Concerning your history of drug used which include in prescription, non-prescription, vitamins & supplements, nutritional products just inform the doctor. While using Mabtas RA 500mg do not take any vaccination or immunization without taking advice from doctors. Allergic condition against Mabtas RA 500mg or any other medication inform your doctor. Avoid use of Mabtas RA 500mg if you are pregnant because it will harm the baby unborn, while using Mabtas RA 500mg cause correct birth control to prohibit pregnancy and for at least 2 weeks after your treatment ends. Mabtas RA 500mg may affect the ability to have children in women. Inform your doctor if you planning to pregnant.

  3. Side Effects Common effects: fever and chills (flu lik symptoms) Less common side effects: Weakness; nausea; headache; cough; dyspnae; pharyngitis Drug Interaction Mabtas RA 500mg drug interaction has limited data is available at present. Combination with fludarabine or cyclophosphamide has no effects in pharmacokinetics in CLL patients. Combination with methotrexate had no effects in pharmacokinetics. Missed Dose If a dose missed to take at the time then have it suddenly before next dose timing, if time reach for next dose, then skip missed dose and continue and continue the regular schedule. Do not have 2 doses at a same time. Storage Store at 20C – 30C. Use the drug before expiry date. Protected from direct sunlight. Do not freeze or shake. Keep away from the childerns. Discard the unused drug by asking the advice from doctor or pharmacist.

More Related